ZenaTech, Inc. (NASDAQ: ZENA) (FSE: 49Q) (BMV: ZENA), a technology solutions provider specializing in AI-powered drones, Drone as a Service (DaaS), enterprise software and quantum computing, announced that its ZenaDrone subsidiary has signed a memorandum of understanding (MOU) with Rattler Medical Inc. to develop and manufacture a drone-based battlefield blood delivery system. The proposed system will combine ZenaDrone's cargo drone capabilities with Rattler Medical's temperature-controlled blood transport containers to deliver blood to military medical personnel more quickly while reducing reliance on ground transportation in combat environments. The initiative matters because timely access to blood is critical for saving lives on the battlefield, and delivering it by drone could bypass contested ground routes and reduce risks to personnel. Under the agreement, the companies plan to develop and test a flying prototype within two to three months, evaluating delivery methods that include aerial release and landing-based deployment. ZenaDrone is targeting a demonstration at a U.S. military facility in summer 2027. The initiative expands ZenaTech (NASDAQ: ZENA) (FSE: 49Q) (BMV: ZENA)'s defense portfolio into battlefield medical logistics, with the companies seeking to improve blood resupply capabilities and reduce risks associated with transporting medical supplies through contested areas. To view the full press release, visit https://ibn.fm/xSVke
The strategic implications extend beyond immediate medical logistics. By integrating drone technology into blood delivery, ZenaTech positions itself at the intersection of defense and healthcare innovation, potentially opening new markets and partnerships. The collaboration with Rattler Medical, which specializes in temperature-controlled containers, addresses a key challenge in drone delivery: maintaining the integrity of sensitive medical supplies during flight. Success could lead to broader adoption of drone-based logistics for other critical supplies, such as vaccines or emergency medications, in both military and civilian contexts. For ZenaTech, this MOU aligns with its strategy to advance AI drones for defense applications, including ISR, cargo, and counter-UAS for U.S. defense and NATO allies. The company's operating footprint spans North America, Europe, the Middle East, Asia, and Australia, and it continues to invest in next-generation technologies like drone swarms and quantum computing. To learn more about ZENA, visit https://www.zenatech.com/.
The announcement was distributed through DefenseWireNews, a specialized communications platform focused on defense contractors and mission-critical companies, which is part of the Dynamic Brand Portfolio at IBN. Such platforms provide access to wire solutions via InvestorWire and editorial syndication to 5,000+ outlets, among other services, helping companies like ZenaTech reach a wide audience of investors and industry stakeholders.


